Modality
mAb
MOA
SGLT2i
Target
FcRn
Pathway
JAK/STAT
CRCADPKD
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
Feb 2019
→ Jul 2028
Phase 2Current
NCT03130195
895 pts·ADPKD
2019-02→2028-07·Active
895 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-07-152.3y awayPh3 Readout· ADPKD
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2/3
Active
Catalysts
Ph3 Readout
2028-07-15 · 2.3y away
ADPKD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03130195 | Phase 2/3 | ADPKD | Active | 895 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |